In EDS ansehen

Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology

Gespeichert in:
Bibliographische Detailangaben
Titel: Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology
Autoren: Gourdy, Pierre, Bachelot, Anne, Catteau-Jonard, Sophie, Chabbert-Buffet, Nathalie, Christin-Maître, Sophie, Conard, Jacqueline, Fredenrich, Alexandre, Gompel, Anne, Lamiche-Lorenzini, Françoise, Moreau, Caroline, Plu-Bureau, Geneviève, Vambergue, Anne, Vergès, Bruno, Kerlan, Véronique
Weitere Verfasser: Calvez, Ghislaine, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Endocrinologie moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), CHU Tenon AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Physiopathologie des maladies génétiques d'expression pédiatrique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie Biologique, Hôpital Hôtel-Dieu Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Diabétologie-Endocrinologie (NICE - Endocrino), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'endocrinologie gynécologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5), Centre national de référence des angioedemes, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Recherche en épidémiologie et biostatistique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Endocrinologie, diabétologie, maladies métaboliques et nutrition (LILLE - Endocrino), Service d'Endocrinologie, Diabétologie et Maladies Métaboliques (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service d'Endocrinologie (CHRU - Endocrino), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)
Quelle: Annales d'Endocrinologie. 73:469-487
Verlagsinformationen: Elsevier BV, 2012.
Publikationsjahr: 2012
Schlagwörter: MESH: Contraception, Oral, MESH: Hyperlipidemias, MESH: Diabetes Mellitus, [SDV]Life Sciences [q-bio], MESH: Metabolic Diseases, Hyperlipidemias, MESH: Contraceptives, MESH: Estrogens, Contraceptives, Oral, Hormonal, 03 medical and health sciences, MESH: Pregnancy, Endocrinology, 0302 clinical medicine, Metabolic Diseases, MESH: Risk Factors, Pregnancy, Risk Factors, Medical, Thromboembolism, Contraceptive Agents, Female, Diabetes Mellitus, MESH: Obesity, Humans, Obesity, MESH: Endocrinology, Societies, Medical, MESH: Lipid Metabolism, MESH: Humans, Hormonal, MESH: Contraceptive Agents, MESH: Cardiovascular Diseases, Estrogens, Lipid Metabolism, 3. Good health, MESH: France, [SDV] Life Sciences [q-bio], Contraception, MESH: Thromboembolism, Cardiovascular Diseases, MESH: Progestins, Female, France, Progestins, MESH: Female, MESH: Societies
Beschreibung: Hormonal contraceptive methods are widely used in France, including not only oral estrogen-progestin combinations but also non-oral estrogen-progestin delivery methods (patches, vaginal rings), as well as oral forms, implants and intra-uterine devices that deliver only a progestin. Hormonal contraception has only a modest impact on lipid and carbohydrate metabolism, but estrogen-progestin contraceptives have been linked to a variety of vascular risks. Overall, the risk of venous thrombosis is multiplied by a factor of about 4, depending on age, the compounds used, and other risk factors (including biological thrombophilia and a personal history of thrombosis), whereas the risk of arterial events is only increased in women with risk factors. Available data suggest there is no excess risk with progestin-based contraceptives, but far fewer studies have been conducted. At the initiative of the French Society of Endocrinology, an expert group met in 2010 in order to reach a consensus on the use of hormonal contraceptive methods in women with vascular or metabolic risk factors, based on available data and international guidelines published by WHO in 2009 and subsequently adapted to the United States context. The following text, intentionally limited to hormonal contraception, is intended to serve as a guide when prescribing in specific clinical situations, such as a family or personal history of arterial or venous thromboembolism, or the existence of cardiovascular risk factors (hypertension, smoking, diabetes, dyslipidemia, obesity).
Publikationsart: Article
Sprache: English
ISSN: 0003-4266
DOI: 10.1016/j.ando.2012.09.001
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/23078975
https://www.ncbi.nlm.nih.gov/pubmed/23078975
https://hal-univ-tlse3.archives-ouvertes.fr/hal-00932019
https://www.em-consulte.com/en/article/764058
https://pubmed.ncbi.nlm.nih.gov/23078975/
https://jhu.pure.elsevier.com/en/publications/hormonal-contraception-in-women-at-risk-of-vascular-and-metabolic-3
https://hal.archives-ouvertes.fr/hal-00932019
Rights: Elsevier TDM
Dokumentencode: edsair.doi.dedup.....d9f2a62d0be61058a7600e78325f11a5
Datenbank: OpenAIRE
Beschreibung
Abstract:Hormonal contraceptive methods are widely used in France, including not only oral estrogen-progestin combinations but also non-oral estrogen-progestin delivery methods (patches, vaginal rings), as well as oral forms, implants and intra-uterine devices that deliver only a progestin. Hormonal contraception has only a modest impact on lipid and carbohydrate metabolism, but estrogen-progestin contraceptives have been linked to a variety of vascular risks. Overall, the risk of venous thrombosis is multiplied by a factor of about 4, depending on age, the compounds used, and other risk factors (including biological thrombophilia and a personal history of thrombosis), whereas the risk of arterial events is only increased in women with risk factors. Available data suggest there is no excess risk with progestin-based contraceptives, but far fewer studies have been conducted. At the initiative of the French Society of Endocrinology, an expert group met in 2010 in order to reach a consensus on the use of hormonal contraceptive methods in women with vascular or metabolic risk factors, based on available data and international guidelines published by WHO in 2009 and subsequently adapted to the United States context. The following text, intentionally limited to hormonal contraception, is intended to serve as a guide when prescribing in specific clinical situations, such as a family or personal history of arterial or venous thromboembolism, or the existence of cardiovascular risk factors (hypertension, smoking, diabetes, dyslipidemia, obesity).
ISSN:00034266
DOI:10.1016/j.ando.2012.09.001